Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.

Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.

NewLimit said Tuesday it has raised a $435 million Series C round at a $3.1 billion post-money valuation.